Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of the Efficacy, Safety, and Tolerability of a Single Oral Administration of CP101 for the Prevention of Recurrent Clostridioides Difficile Infection (CDI)

NCT05153499 is registered in ClinicalTrials.gov with Finch Research and Development LLC. as lead sponsor.

NCT NCT05153499
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05153499 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of the Efficacy, Safety, and Tolerability of a Single Oral Administration of CP101 for the Prevention of Recurrent Clostridioides Difficile Infection (CDI)
Lead sponsor
Finch Research and Development LLC.
Phase
Phase 3
Overall status
Terminated
Start date
November 15, 2021
Completion date
February 24, 2023
Enrollment
19 (actual)
Sites
68

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent c. difficile infection